Welcome to our dedicated page for NU SKIN ENTERPRISES SEC filings (Ticker: NUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NU SKIN ENTERPRISES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NU SKIN ENTERPRISES's regulatory disclosures and financial reporting.
Daniel W. Campbell, a director of Nu Skin Enterprises (NUS), reported open-market sales of Class A common stock on 08/29/2025. The filing shows two disposal transactions: 9,046 shares sold at a weighted-average price of $12.12 and 23,391 shares sold at a weighted-average price of $12.10, for total reported disposals of 32,437 shares. After the transactions the report shows 39,216 shares held directly and 53,375 shares held indirectly, including shares held by an irrevocable family trust and by a limited liability company controlled by the reporting person and his spouse.
Form 144 filed for NuSkin Enterprises, Inc. (NUS) reports a proposed sale of 23,391 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $283,117.65. The filing lists the approximate date of sale as 08/29/2025 and shows 49,497,715 shares outstanding. All 23,391 shares were acquired as gifts from affiliate Daniel Campbell on 11/02/2021, with donor acquisition dates and per-lot amounts totaling the 23,391 shares. The filer reports "Nothing to Report" for securities sold in the past three months and includes the standard representation that no undisclosed material adverse information about the issuer is known.
Nu Skin Enterprises (NUS) Form 144 filing reports a proposed sale of 9,046 shares of Common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $109,635.71. The shares represent restricted stock that vested under the issuer's registered plan on 04/24/2012 (4,046 shares) and 05/24/2018 (5,000 shares), with cash payment recorded on the respective vesting dates. The filer states there were no securities sold in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.